Oppenheimer Asset Management Inc. Purchases 1,992 Shares of Natera, Inc. $NTRA

Oppenheimer Asset Management Inc. increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 11.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,736 shares of the medical research company’s stock after purchasing an additional 1,992 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Natera were worth $3,334,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock worth $1,752,611,000 after buying an additional 77,357 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. raised its position in Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after purchasing an additional 660,538 shares during the last quarter. Invesco Ltd. boosted its stake in Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after purchasing an additional 245,719 shares in the last quarter. Finally, Maverick Capital Ltd. boosted its stake in Natera by 19.7% in the first quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock worth $231,173,000 after purchasing an additional 268,715 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total value of $398,670.00. Following the completion of the sale, the insider owned 123,059 shares in the company, valued at $16,353,310.51. This represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the sale, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 57,374 shares of company stock valued at $9,108,022. 5.63% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Cowen reaffirmed a “buy” rating on shares of Natera in a report on Friday, August 8th. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target on the stock in a research note on Monday. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $194.89.

Natera Stock Down 1.4%

Shares of Natera stock opened at $189.57 on Wednesday. The business has a fifty day simple moving average of $172.50 and a 200 day simple moving average of $161.04. The stock has a market cap of $26.02 billion, a PE ratio of -99.25 and a beta of 1.74. Natera, Inc. has a 12 month low of $119.29 and a 12 month high of $198.99.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.